POEMS Syndrome Gets a Modern Treatment Roadmap With 80% 10-Year Survival

POEMS syndrome is a rare, complex paraneoplastic disorder driven by a lambda-restricted, low-tumor-burden plasma cell neoplasm. Its name is an acronym for its cardinal features: Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes. Because patients may present with what resembles monoclonal gammopathy of undetermined significance (MGUS), the diagnosis is frequently delayed. Key distinguishing features include peripheral neuropathy, thrombocytosis, and extracellular volume overload — symptoms that should prompt clinicians to look beyond a routine MGUS workup.

This 2025 educational review from the American Society of Hematology, authored by Dr. Angela Dispenzieri of Mayo Clinic, consolidates decades of clinical experience and case series data into a practical framework for diagnosis and management. The paper emphasizes that POEMS must be recognized as a distinct entity requiring targeted evaluation, including assessment of VEGF levels, bone surveys, and nerve conduction studies, rather than being managed under a generic monoclonal gammopathy protocol.

On the treatment front, autologous stem cell transplantation (ASCT) remains the preferred approach for eligible patients, with evidence supporting durable long-term remissions — notably without the need for maintenance therapy. Patients who achieve a complete hematologic response demonstrate an impressive 88% progression-free survival. These outcomes are particularly striking given that they were achieved before the widespread adoption of modern immunotherapies including bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell therapies. The 10-year overall survival rate approaches 80%, situating POEMS among the more treatable plasma cell dyscrasias despite its complexity.

For patients not eligible for ASCT, treatment paradigms mirror those used in multiple myeloma or solitary plasmacytoma of bone, including radiation therapy for localized disease and novel agent-based regimens. Supportive care is described as highly specific to POEMS, given the multisystem nature of the disease — requiring coordination across neurology, endocrinology, cardiology, and hematology.

The review closes with a detailed case presentation of a patient with a below-average outcome, deliberately chosen to highlight the long-term challenges of POEMS management: disease relapse, organ dysfunction, and the cumulative burden of multisystem involvement. This case-based approach underscores the importance of sustained follow-up and individualized care planning. As newer immune-based therapies enter clinical practice, outcomes for POEMS patients are expected to improve further, making early and accurate diagnosis increasingly critical.